Dexcom (DXCM) Executive Chair Kevin Sayer Sells 26,756 Shares

What Happened
Kevin R. Sayer, Executive Chair and Director of Dexcom (DXCM), sold 26,756 shares in an open-market transaction on July 20, 2026. The weighted average sale price was $76.32, producing gross proceeds of approximately $2,041,999. This was a sale (not a purchase) and was executed pursuant to a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: 2026-07-20; Form 4 filed: 2026-07-21 (timely filing).
• Shares sold: 26,756; weighted average sale price: $76.32; price range across multiple trades: $75.80–$76.62.
• Gross proceeds: ~$2,041,999.
• Planned sale: Executed under a 10b5-1 plan adopted by Mr. Sayer on February 18, 2026 (Footnote F1).
• Reporting details: F2 notes the transaction occurred in multiple trades and the reporting person will provide full trade-by-trade info on request.
• Holdings note: The filing indicates reported beneficial ownership includes 106,972 unvested restricted stock units (RSUs) — 32,749 granted 3/8/2026 vesting through 3/8/2027; 56,993 granted 3/8/2025 vesting through 3/8/2028; 17,230 granted 3/8/2024 vesting through 3/8/2027 (Footnote F3). The excerpt provided does not list the total shares owned after the sale.

Context
Sales made under a 10b5-1 plan are typically pre-arranged and can be routine liquidity events; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases generally carry more weight as a potential bullish signal; this filing documents a planned sale.